Across TCGA pan-cancer cohorts, PYGB Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PYGB data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher PYGB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PYGB expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
UCS, PRAD, and SKCM are the cancer types where PYGB Mutation most reproducibly stratifies survival.